The Ilex Medical Ltd. (TASE:ILX) share price is surging on a large turnover in TASE trading. The company today reported that its sub-subsidiary in South Africa had won a tender issued by the South African National Blood Service (SANBS) for the replacement of blood testing systems to detect and identify viruses. The tender was decided following a six-month contest between international competitors.
As part of the tender, Ilex South Africa will replace the Tigris systems manufactured by Grifols currently installed at SANBS with new Panther systems. Under the tender terms, the duration of the contract is five years, with a five-year extension option.
This triumph follows a previous win by Ilex South Africa at the Capetown blood bank, which means that Ilex South Africa will now supply the tests for detecting and identifying viruses at many of the blood banks in South Africa.
The value of the tender is estimated at $110 million over the initial contract period. Ilex believes that this is the most significant tender it has ever won.
Supply is slated to begin in the fourth quarter of the year for the purpose of changeover and optimal transition from the Tigris system to the Panther system. Routine operation of the new system will begin in January 2016.
Ilex also said that a number of blood banks in South Africa had closely followed the tender and its results in order to decide on the purchase of systems for the detection and identification of blood viruses, and the company believed that the tender results would influence their decision.
Published by Globes [online], Israel business news - www.globes-online.com - on September 16, 2015
© Copyright of Globes Publisher Itonut (1983) Ltd. 2015